Neurological adverse effect of adalimumab in sarcoidosis: a case of severe neuropathy

Background Anti–tumor necrosis factor-alpha (anti-TNF) agents are recommended as third-line therapy in refractory pulmonary sarcoidosis. Neurological adverse events, including peripheral neuropathy, are rare and typically occur months after treatment initiation.Case presentation We describe a 30-year-old man with long-standing pulmonary and ocular sarcoidosis who developed rapidly progressive peripheral neuropathy shortly after initiation of adalimumab. The patient had been treated for several years with glucocorticoids, methotrexate, and infliximab, but was switched to adalimumab due to high titers of anti-infliximab antibodies and refractory ocular disease. After two subcutaneous injections of adalimumab (40 mg biweekly), he developed sensory symptoms in all extremities, progressing within days to painful hypersensitive neuropathy and distal motor weakness. Electrophysiological studies demonstrated an axonal sensorimotor neuropathy. Cerebrospinal fluid analysis showed inflammatory changes with elevated protein levels, while MRI of the central nervous system was normal. Adalimumab was discontinued, and treatment with high-dose glucocorticoids and gabapentin resulted in partial clinical improvement.Conclusion Rapid-onset axonal peripheral neuropathy following adalimumab is rare, particularly in sarcoidosis. This case underscores the importance of early recognition and discontinuation of anti-TNF therapy.

Authors

Institutions

Publication Details

Journal
European Clinical Respiratory Journal
Published
2026-11-17
DOI
https://doi.org/10.1080/20018525.2026.2725996
Primary Topic
Sarcoidosis and Beryllium Toxicity Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Neurological adverse effect of adalimumab in sarcoidosis: a case of severe neuropathy

Søren Sperling, Elisabeth M. Bendstrup, Janne Møller, Anette Sandahl Ullmann
1 links
European Clinical Respiratory Journal
Sarcoidosis and Beryllium Toxicity Research
article

Neurological adverse effect of adalimumab in sarcoidosis: a case of severe neuropathy

Søren Sperling, Elisabeth M. Bendstrup, Janne Møller, Anette Sandahl Ullmann
article en

Abstract

Background Anti–tumor necrosis factor-alpha (anti-TNF) agents are recommended as third-line therapy in refractory pulmonary sarcoidosis. Neurological adverse events, including peripheral neuropathy, are rare and typically occur months after treatment initiation.Case presentation We describe a 30-year-old man with long-standing pulmonary and ocular sarcoidosis who developed rapidly progressive peripheral neuropathy shortly after initiation of adalimumab. The patient had been treated for several years with glucocorticoids, methotrexate, and infliximab, but was switched to adalimumab due to high titers of anti-infliximab antibodies and refractory ocular disease. After two subcutaneous injections of adalimumab (40 mg biweekly), he developed sensory symptoms in all extremities, progressing within days to painful hypersensitive neuropathy and distal motor weakness. Electrophysiological studies demonstrated an axonal sensorimotor neuropathy. Cerebrospinal fluid analysis showed inflammatory changes with elevated protein levels, while MRI of the central nervous system was normal. Adalimumab was discontinued, and treatment with high-dose glucocorticoids and gabapentin resulted in partial clinical improvement.Conclusion Rapid-onset axonal peripheral neuropathy following adalimumab is rare, particularly in sarcoidosis. This case underscores the importance of early recognition and discontinuation of anti-TNF therapy.

European Clinical Respiratory JournalVol. 13(1)
Aarhus University (DK), Aarhus University Hospital (DK)
Good health and well-being
Sarcoidosis and Beryllium Toxicity Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon